BHCM
GYRE icon

Brevan Howard Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Brevan Howard Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,808
Closed -$96.2K – 2267
2026
Q1 		$96.2K Buy
+13,808
New +$107K ﹤0.01% 2030

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Brevan Howard Capital Management's GYRE Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2026, closing a stake of 13,808 shares — an estimated $96.2K sold.

Brevan Howard Capital Management first reported a position in GYRE in Q1 2026 and held it in 1 quarter. The position peaked at $96.2K in Q1 2026. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Gyre Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 13,808 Gyre Therapeutics shares in Q2 2026, an estimated $96.2K.
  • Brevan Howard Capital Management first reported a position in Gyre Therapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Gyre Therapeutics position peaked at $96.2K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.